anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Quote

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 18,554
Current window 15,601-15,630
Pages 619
Rows per page 30
Component: Quoteclear collectionreset all
18 30 60

Component

15,601-15,630 of 18,554

filter-aware
353
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
354
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
355
The slide uses a Q&A format to build a case for market substitution risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
361
The slide uses direct quotes from a pediatric endocrinologist to undermine the viability of a drug (Vykat/diazoxide).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
364
The slide uses verbatim quotes from a consultation call to highlight a discrepancy between the company's risk management (handouts) and the physician's expectations of transient vs. permanent side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
365
The slide uses direct quotes from an endocrinologist to undermine the product's differentiation and pricing justification.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
366
The slide uses direct quotes to highlight a potential discrepancy between marketing claims and clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
371
The slide uses a Q&A transcript format to expose potential conflicts of interest between a company (Soleno) and a patient association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
372
The slide uses a Q&A transcript format to highlight potential misinformation or manipulation by study investigators regarding drug efficacy timelines.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
374
The slide uses a Q&A transcript format to expose potential flaws in clinical trial methodology and physician sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
376
The slide uses Q&A transcripts to undermine the value proposition of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
377
The slide uses a Q&A format to expose a gap in the company's support infrastructure.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
382
The slide uses a Q&A transcript format to highlight the physician's frustration and lack of guidance from the manufacturer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
387
The slide uses Q&A transcripts to undermine the credibility of the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
389
The slide uses a Q&A format to highlight expert skepticism regarding the drug's necessity and cost-effectiveness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
395
The slide uses a Q&A format to highlight the physician's reluctance to prescribe Vykat and their familiarity with the risks of diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
396
The slide uses direct quotes from a pediatric endocrinologist to undermine the company's commercial narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
407
The slide presents a summary of an expert interview, highlighting the endocrinologist's preference for GLP-1s over Vykat for PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
409
The slide uses direct quotes to build a narrative of expert doubt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
410
The slide uses Q&A transcripts to highlight the expert's skepticism regarding Vykat's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
411
The slide uses a Q&A format to highlight the administrative burden and slow approval process for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
412
The slide uses a Q&A transcript format to validate the claim of trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
413
The slide uses a Q&A format to present primary research findings from a consultation call.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
414
The slide uses Q&A transcript format to build credibility for the thesis that generic substitution is common practice among specialists.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
415
Includes a Q&A transcript snippet highlighting anecdotal evidence.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
01
Slide 1
The slide uses aggressive, accusatory language typical of short-seller research reports.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The Monster1 hit
06
The slide uses strong, accusatory language to frame the company's financial reporting as fraudulent.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
08
The slide uses comparative analysis against industry peers (ASML, Applied Materials, Lam, KLA) and historical precedents (Toshiba, MagnaChip) to build a case for financial manipulation.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
10
The slide uses strong, accusatory language to frame a technical failure as a financial fraud.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
11
The slide uses strong, accusatory language ('fatally flawed', 'furious', 'terrible') to frame the technical issues as a business crisis.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The StruggleLoop · Aha Moment1 hit